12 March 2018 - - Indianapolis, Indiana-based global pharmaceuticals specialist Eli Lilly and Company (NYSE: LLY) has agreed to extend its collaboration with the European Foundation for the Study of Diabetes (EFSD) and JDRF for the European Programme in Type 1 diabetes research through 2020, the company said.
The programme, which began in 2015, encourages research that advances knowledge about type 1 diabetes by providing grants up to EUR 100,000 to nonprofit institutions and groups in Europe. Nineteen research grants have been awarded to institutions and groups across Europe since 2015.
including, but not limited to, research in beta cell biology and regeneration, autoimmunity/immunoregulation, novel concepts and biomaterials for beta cell replacement, and novel therapies for improved glycemic control,
The goals of the programme are to promote and support high quality biomedical and clinical type 1 diabetes research, expedite the practical application of scientific advances, and encourage clinical translation of research in Europe.
The EFSD was created by the European Association for the Study of Diabetes to provide funding in all areas of diabetes research across the entire European Region. The aims of EFSD are to encourage and support groundbreaking diabetes research and to promote the next generation of leading diabetes researchers.
JDRF funds T1D research to accelerate breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, the organisation has invested more than USD2 bn in research funding since inception. It has staff and volunteers throughout the United States and at six international affiliates.
Lilly has been in diabetes care since 1923, when it introduced the world's first commercial insulin.